Eurobio-Scientific SA (E8TN) Price & Analysis
E8TN Stock Chart & Stats
- Day’s Range
- EUR 25.40 - EUR 25.90
- 52-Week Range
- EUR 19.00 - EUR 26.00
- Previous Close
- EUR 26.00
- Volume
- 0
- Average Volume (3M)
- 80
- Market Cap
- EUR 258.39M
- Enterprise Value
- EUR 203.86M
- Total Cash (Recent Filing)
- EUR 26.34M
- Total Debt (Recent Filing)
- EUR 14.74M
- Price to Earnings (P/E)
- 37.6
- Beta
- 0.15
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage
Debt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.
Positive Cash Generation
Positive operating and free cash flow in every period shown demonstrates that the business converts operations into internally generated funds. That supports ongoing investment and resilience, although recent deterioration means this strength should not be treated as unqualified.
Recurring Consumables Model
Sales of continuously consumed IVD tests, reagents, and laboratory consumables can create repeat purchasing, while distribution and service offerings broaden the revenue base. This supports durable customer relationships and more resilient demand across clinical and research markets.
Bears Say
Lower Margin Durability
Net margin of about 2.9% in 2025, versus exceptionally high levels in 2021–2022, shows earnings power has reset lower. Even with gross margin around 40–46%, thinner operating profitability leaves less room to absorb execution pressure or reinvest.
Weaker Free Cash Flow
Free cash flow fell about 16% year over year in 2025 and was far below 2021–2022 levels. This weakening reduces internally funded investment capacity and makes shareholder cash generation less dependable, despite remaining positive overall.
Volatile Capital Returns
Historical returns on equity have swung materially, and 2025 ROE is shown as zero. Such inconsistency makes it harder to judge the durability of capital productivity and indicates that reported earnings have not translated into stable returns for shareholders.
Eurobio-Scientific SA News
E8TN FAQ
What was Eurobio-Scientific SA’s price range in the past 12 months?
What is Eurobio-Scientific SA’s market cap?
When is Eurobio-Scientific SA’s upcoming earnings report date?
How were Eurobio-Scientific SA’s earnings last quarter?
Is Eurobio-Scientific SA overvalued?
Does Eurobio-Scientific SA pay dividends?
What is Eurobio-Scientific SA’s EPS estimate?
How many shares outstanding does Eurobio-Scientific SA have?
What happened to Eurobio-Scientific SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Eurobio-Scientific SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Eurobio-Scientific SA
Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Denis Fortier
- Employees
- 443
- Website
- www.eurobio-scientific.com
- Address
- 7 avenue de Scandinavie, Les Ulis, IF, 91953, FR
Eurobio-Scientific SA (E8TN) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |





